Jeffrey W. Sherman's most recent trade in Larimar Therapeutics Inc was a trade of 5,000 Common Stock done at an average price of $5 . Disclosure was reported to the exchange on Feb. 27, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Larimar Therapeutics Inc | Jeffrey W. Sherman | Director | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 27 Feb 2026 | 5,000 | 5,000 | - | 5 | 25,000 | Common Stock |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.66 per share. | 28 Aug 2025 | 47,040 | 261,420 (0%) | 0% | 6.7 | 313,286 | Common Stock |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2025 | 47,040 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale of securities on an exchange or to another person at price $ 7.92 per share. | 28 Aug 2025 | 42,232 | 219,188 (0%) | 0% | 7.9 | 334,515 | Common Stock |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 50,000 | 214,380 (0%) | 0% | 0 | Common Stock | |
| Larimar Therapeutics Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2025 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 50,000 | 164,380 (0%) | 0% | 0 | Common Stock | |
| Larimar Therapeutics Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2024 | 19,000 | 19,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Other type of transaction at price $ 0.00 per share. | 15 Mar 2024 | 6,502 | 114,380 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 42,500 | 107,878 (0%) | 0% | 0 | Common Stock | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Jan 2023 | 33,795 | 2,376 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Jan 2023 | 33,795 | 83,109 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.05 per share. | 10 Jan 2023 | 3,368 | 39,539 (0%) | 0% | 113.0 | 380,752 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.10 per share. | 10 Jan 2023 | 3,368 | 36,171 (0%) | 0% | 113.1 | 380,921 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 51,132 | 65,562 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.24 per share. | 04 Jan 2023 | 22,655 | 42,907 (0%) | 0% | 113.2 | 2,565,452 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 18,397 | 18,397 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 12,095 | 0 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 9,318 | 4,654 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 9,314 | 9,314 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 7,257 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 6,348 | 12,696 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 113.29 per share. | 04 Jan 2023 | 5,187 | 49,314 (0%) | 0% | 113.3 | 587,635 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 4,834 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2023 | 1,966 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 21,772 | 24,147 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 21,772 | 0 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.80 per share. | 01 Jan 2023 | 9,717 | 14,430 (0%) | 0% | 113.8 | 1,105,795 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 21,772 | 21,772 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Dec 2022 | 13,972 | 13,972 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 111.45 per share. | 12 Dec 2022 | 21,378 | 84,430 (0%) | 0% | 111.4 | 2,382,484 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2022 | 8,531 | 61,475 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2022 | 8,531 | 2,375 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 111.44 per share. | 12 Dec 2022 | 6,974 | 54,501 (0%) | 0% | 111.4 | 777,208 | Ordinary Shares |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 15,000 | 65,378 (0%) | 0% | 0 | Common Stock | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 110.02 per share. | 06 Apr 2022 | 42,009 | 10,629 (0%) | 0% | 110.0 | 4,621,872 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 12,304 | 50,062 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 12,304 | 46,989 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2022 | 8,531 | 164,469 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.14 per share. | 18 Mar 2022 | 8,531 | 52,638 (0%) | 0% | 22.1 | 188,876 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 8,169 | 52,944 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 8,169 | 44,107 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 5,287 | 52,276 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 18 Mar 2022 | 5,287 | 44,775 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2022 | 5,354 | 0 | - | - | Restricted Stock Units (RSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2022 | 5,354 | 61,665 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.42 per share. | 21 Jan 2022 | 2,372 | 59,293 (0%) | 0% | 86.4 | 204,988 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 52,570 | 61,685 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 04 Jan 2022 | 37,675 | 56,311 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 32,301 | 93,986 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2022 | 19,044 | 19,044 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 12,261 | 0 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 12,095 | 12,095 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Jan 2022 | 10,729 | 9,115 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Jan 2022 | 10,729 | 37,808 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 9,678 | 4,834 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 9,314 | 18,628 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2022 | 9,222 | 9,223 | - | - | Restricted Stock Units (RSU) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Jan 2022 | 50 | 37,758 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Oct 2021 | 10,729 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.61 per share. | 27 Oct 2021 | 10,729 | 19,844 (0%) | 0% | 7.6 | 81,648 | Ordinary Shares |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 50,378 | 50,378 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 47,040 | 47,040 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 31,360 | 31,360 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 31,360 | 31,360 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 19,650 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 19,650 | 19,650 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Sep 2021 | 46,271 | 10,729 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 21 Sep 2021 | 46,271 | 9,115 (0%) | 0% | 110 | 5,089,810 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.61 per share. | 21 Sep 2021 | 46,271 | 55,386 (0%) | 0% | 7.6 | 352,122 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Sep 2021 | 4,042 | 9,115 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Sep 2021 | 4,042 | 27,079 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 14,514 | 14,514 | - | - | Performance Restricted Stock Units (PSUs) | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 7,257 | 16,372 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 102.50 per share. | 28 Jul 2021 | 3,215 | 13,157 (0%) | 0% | 102.5 | 329,538 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Jul 2021 | 66,730 | 14,402 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Jul 2021 | 66,730 | 66,730 (0%) | 0% | 0 | Ordinary Shares | |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 01 Jul 2021 | 54,789 | 128,845 (0%) | 0% | 95.0 | 5,205,097 | Ordinary Shares |
| Horizon Therapeutics Plc | Jeffrey W. Sherman | EVP and Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 95.00 per share. | 01 Jul 2021 | 5,287 | 9,115 (0%) | 0% | 95 | 502,265 | Ordinary Shares |
| Xeris Biopharma Holdings Inc | Jeffrey W. Sherman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) |